SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 7.46% Stake in Kura Oncology

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 7.46% in Kura Oncology, Inc., totaling 5.8 million shares of common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G indicating their beneficial ownership in Kura Oncology, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 5,800,000 shares of Kura Oncology, Inc. common stock.
• This ownership represents 7.46% of the total outstanding shares of Kura Oncology, Inc.
• The percentage is calculated based on 77,763,750 shares outstanding as of November 4, 2024, as reported in Kura Oncology's Form 10Q filed on November 7, 2024.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is also deemed to beneficially own the shares.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting and shared dispositive power over the 5,800,000 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it is a mandatory disclosure of beneficial ownership. The disclosure of a significant stake by an institutional investor can be seen as mildly positive, indicating investor confidence, but it does not contain new operational or financial news from the issuer.

Positives

• The disclosure of a significant stake by an institutional investor like Armistice Capital, LLC, and its managing member Steven Boyd, can be viewed positively as it indicates confidence in Kura Oncology, Inc.

Negatives

• The document itself does not contain any negative information regarding Kura Oncology, Inc.'s operations or financial performance.

Risks

• The document does not explicitly mention risks related to Kura Oncology, Inc.'s business operations or financial health. It is a disclosure of ownership.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by Armistice Capital, LLC, an investment manager, in Kura Oncology, Inc., a company likely operating in the biotechnology or pharmaceutical sector. Such institutional investments are common in the industry, reflecting investor interest in specific companies' pipelines or market positions.

Comparison to Industry Standards

• NA (A Schedule 13G filing does not provide data for direct comparison to industry-specific operational or financial benchmarks. It solely reports beneficial ownership.)

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake might be viewed positively, potentially signaling confidence in the company's future, which could influence investor sentiment.
• Management: Awareness of a large institutional holder may influence management's strategic decisions, though the filing states the stake is not for control purposes.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1% of the class) or if their intent changes.

Key Dates

Keywords

Kura Oncology, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals